PT-141
Melanocortin agonist researched for libido and arousal pathways.
PT-141
Background
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone that acts as a non-selective agonist at melanocortin receptors, with activity at the MC4 receptor implicated in central regulation of sexual response. Unlike vasoactive agents, its proposed mechanism is centrally mediated within the nervous system.
Phase 3 trials (the RECONNECT studies) evaluated bremelanotide for hypoactive sexual desire disorder in premenopausal women, providing a controlled clinical evidence base for that specific indication.
Selected literature
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics and Gynecology. 2019;134(5):899-908.
- Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health. 2016;12(3):325-337.
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Bremelanotide is marketed as Vyleesi(R) by Palatin Technologies (originally developed with AMAG Pharmaceuticals). That trademark is the property of its owner. Catalyst Research Labs is not affiliated with, endorsed by, or sponsored by Palatin Technologies. Supplied as reference material only.
